Frontage (HKG:1521) recorded a net profit of $5.6 million for the nine months ended Sept. 30, up from $200,000 a year prior, a Tuesday Hong Kong bourse filing said.
The biotech firm's revenue rose 0.2% to $191.4 million in the three quarters.
Frontage (HKG:1521) recorded a net profit of $5.6 million for the nine months ended Sept. 30, up from $200,000 a year prior, a Tuesday Hong Kong bourse filing said.
The biotech firm's revenue rose 0.2% to $191.4 million in the three quarters.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。